Chodak on Urology

• Combo Data Creates New Choices in Metastatic Prostate Cancer   New, more effective antiandrogens are improving outcomes for men with newly diagnosed metastatic prostate cancer. The challenge is in choosing which to use, says Dr Chodak.
  Medscape Urology, August 2017
• New Data Change Metastatic Prostate Cancer Treatment Paradigm   Dr Chodak reviews results of the LATITUDE trial, which compared ADT alone versus ADT with abiraterone acetate plus prednisone.
  Medscape Urology, August 2017
• 4K Test May Help Avert Unnecessary Prostate Cancer Treatment   New data make a very strong case for incorporating the 4K test into standard management of men advised to undergo prostate biopsy because of PSA test results, according to Dr Gerald Chodak.
  Medscape Urology, August 2017
• PSA Density: A Better Predictor of Prostate Cancer Risk?   How accurate is PSA density for predicting prostate cancer? Dr Chodak reviews new research in Urology comparing PSA density with PSA alone.
  Medscape Urology, August 2017
• Does Active Surveillance Increase Metastasis Risk for PCa?   Dr Gerald Chodak reviews new data on active surveillance for low-risk prostate cancer and its effect on metastasis-free and prostate cancer-specific survival.
  Medscape Urology, June 2017
• Can MRI Replace Biopsy for Prostate Cancer Surveillance?   Dr Chodak discusses multiparametric MRI versus biopsy in active surveillance of men with prostate cancer.
  Medscape Urology, May 2017
• USPSTF Casts Net Wider for PSA Screening; Education Is Key   Dr Chodak discusses proposed USPSTF prostate cancer screening guidelines and offers much needed education for patients on the pros and cons of screening.
  Medscape Urology, April 2017
• Disturbing Pattern of Recurrence in Men Post Radical Prostatectomy   Dr Gerald Chodak discusses the clinical implications of new data on recurrence patterns in prostate cancer patients following radical prostatectomy.
  Medscape Urology, April 2017
• What Is the Best Treatment for High-Grade Prostate Cancer?   Dr Chodak explores several unanswered questions posed by a multicenter analysis comparing treatments in more than 1000 advanced prostate cancer patients.
  Medscape Urology, March 2017
• Prostate Cancer Mortality in Men With a Negative Initial Biopsy   Dr Chodak discusses the next steps for prostate cancer patients following a negative initial biopsy, based on 20 years of data analyzed in a recent population-based study of prostate cancer mortality risk.
  Medscape Urology, March 2017
• Photodynamic Therapy for Prostate Cancer Shows Early Promise   Initial study results using photodynamic therapy for shrinking prostate cancer size are promising and demonstrate the need for studies with longer follow-up and larger study groups.
  Medscape Urology, February 2017
• The Case Against Fluoroquinolones for Prostate Biopsy   While the FDA and AUA slightly differ on their fluoroquinolone safety warnings for prostate biopsy, Dr Gerald Chodak advises against its use due to the possible severe side effects.
  Medscape Urology, February 2017
• HIFU-Hemiablation for Treatment of Prostate Cancer?   Dr Gerald Chodak questions the value of the IDEAL study to evaluate HIFU-hemiablation as the primary treatment for prostate cancer.
  Medscape Urology, January 2017
• Brachytherapy Plus EBRT for Intermediate-Risk Prostate Cancer   Questions persist about the benefits of combination therapy vs brachytherapy alone, despite findings of a new study, says Dr Gerald Chodak.
  Medscape Urology, January 2017
• Are Meta-analyses Reliable? The Prostate Cancer Experience   Dr Gerald Chodak suggests that the Wallis study has too many biases to recommend surgery over radiation for localized prostate cancer treatment.
  Medscape Urology, December 2016
• Benefit Seen to Initiating Salvage Radiation at Lower PSA   Dr Gerald Chodak discusses a retrospective study whose results challenge the commonly accepted >/= 0.5 PSA threshold for starting radiation.
  Medscape Urology, December 2016
• PSA Testing: A New, Simpler Way?   Dr Chodak reviews a new algorithm intended to simplify PSA testing. But is it ready for prime time?
  Medscape Urology, November 2016
• Digital Rectal Exam's Role Unclear in Prostate Cancer   Dr Gerald Chodak explains how the recent PLCO Trial has affected the use of this already debated testing method.
  Medscape Urology, October 2016
• Lessons of ProtecT: Trial Clarifies Prostate Cancer Options   Dr Gerald Chodak explains what this excellent, but not flawless, 10-year study may mean for active surveillance and PSA screening.
  Medscape Urology, September 2016
• Are Metastatic Prostate Cancer Diagnoses Really Increasing?   A recent study suggested an increase in metastatic disease at the time of prostate cancer diagnosis, but the authors' analysis may have been flawed, argues Dr Gerald Chodak.
  Medscape Urology, September 2016